Infoline (9 - 5)   02 9879 2600  or   1800 985 944

Latest News

Schizophrenia research institute logo

November 9, 2015 
Inika Gillis

Clinical trial: Neurocognitive markers of affective and psychotic disorders

Many people experience a combination of psychotic and mood symptoms that change over time, and often do not fit neatly into the diagnostic categories of ‘schizophrenia’ or ‘bipolar disorder’. more...

Australian Journal of PharmacyAustralian Journal of Pharmacy
November 3, 2015
Megan Haggan

New atypical antipsychotic for schizophrenia has ‘negligible’ weight effect

Prof David Castle from Melbourne says one of the challenges that clinicians face in treating schizophrenia with medication is unwanted weight gain and changes in metabolic profile. “The implications of excessive weight gain mustn’t be overlooked. Treating the mind should not be at the expense of the body.” Latuda (lurasidone HCl) will be avail on PBS from 1 Nov.  more...

Columbia University Medical CentreNovember 6, 2015
CUMC Newsroom

New study identifies better option for some people with treatment-resistant schizophrenia

Patients who don't respond to standard antipsychotic medications for schizophrenia  have better outcomes if they begin taking the drug clozapine, an atypical antipsychotic drug, instead of moving on to another standard antipsychotic, says new study.more...

MNT logoMedical News Today
November 7, 2015

Antipsychotic drugs linked to brain tissue loss in patients with schizophrenia

University of Brescia (Italy) study found that the long-term use of first-generation antipsychotics was associated with greater progressive loss of gray matter, while the use of second-generation medications "did not correlate with GM [gray matter] volume changes over time and was not associated with cortical tissue loss." more...

AAAS logoMichael Balter
5 February, 2014

Schizophrenia: Time to Flush the Meds?

Cognitive Behaviour Therapy (CBT) may be a better option for some patients. more...